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A b s t r a c t
Introduction: Currently, invasive cardiology techniques are the preferred method of treatment for patients with ST-elevation 
myocardial infarction (STEMI). Improving the care of patients with STEMI is possible by minimizing the time that elapses from the 
onset of pain to the start of treatment. As studies indicate, early pharmacotherapy, especially with antiplatelet and anticoagulant 
medications, allows for their early effectiveness.
Aim: To assess the influence of early administration of antiplatelet (clopidogrel) and anticoagulant medications in the pre-hos-
pital period in patients with ST-elevated myocardial infarction on the frequency of in-hospital deaths and on the left ventricular 
ejection fraction evaluated at hospital discharge.
Material and methods: In this study, a retrospective analysis of 573 patients hospitalized due to ST-segment elevation myo-
cardial infarction in one of Krakow’s hospitals from January 2011 to December 2015 (excluding the whole of 2013) was used as 
a research method. 
Results: As many as 97% of patients received pre-hospital pharmacotherapy, but only 46.0% of respondents received unfrac-
tionated heparin, and 19.2% received clopidogrel. The in-hospital mortality rate was 6.7%, but among patients prehospitally treated 
with clopidogrel and unfractionated heparin, the in-hospital mortality rate was 1.1%. Prehospital administration of clopidogrel 
significantly decreased the possibility of reduced left ventricular ejection fraction (OR = 0.27; 95% CI: 0.09–0.90).
Conclusions: Among pre-hospital procedures, only administration of a second antiplatelet drug (clopidogrel) significantly de-
creased the risk of reduced left ventricular ejection fraction, and administration of clopidogrel or heparin, or a combination of both, 
significantly decreased the risk of in-hospital death in patients with STEMI.
Key words: pre-hospital pharmacotherapy, ST-elevation myocardial infarction, in-hospital prognosis, left ventricular ejection 
fraction.
S u m m a r y
Invasive cardiology techniques are the preferred method of treatment for patients with ST-elevation myocardial infarc-
tion. Improving the care of patients with ST-elevation myocardial infarction is possible by minimizing the time between 
the onset of pain and the start of treatment. As studies indicate, early pharmacotherapy, especially with antiplatelet and 
anticoagulant medications, allows for their early effectiveness. The aim of the study was to assess the influence of early 
administration of a second antiplatelet and anticoagulant medications in the pre-hospital period in patients with ST-elevated 
myocardial infarction on the frequency of in-hospital deaths and left ventricular ejection fraction evaluated at discharge.
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Introduction
Cardiovascular diseases are among the main caus-
es of death in Poland and worldwide. Of them, ischemic 
heart disease, including myocardial infarction, accounts 
for a significant percentage [1]. Currently, invasive cardi-
ology techniques are the preferred method of treatment 
in patients with ST-segment elevation myocardial infarc-
tion (STEMI). Early pharmacotherapy, especially involving 
antiplatelet and anticoagulant drugs, is an important 
part of the treatment of patients with acute coronary 
syndromes (ACS). For many years, the MONA regimen 
including administration of morphine, oxygen, nitroglyc-
erin and aspirin was the standard pre-hospital treatment 
of STEMI patients, and after the introduction of common 
access to mechanical reperfusion, it additionally includ-
ed administration of a  clopidogrel loading dose and 
a bolus of unfractionated heparin. The new antiplatelet 
drugs (prasugrel, ticagrelor) have modified the standard 
pre-hospital pharmacotherapy, which nowadays aims at 
individual assessment of each patient and the provision 
of appropriate treatment rather than administration of 
a routine set of medications. Based on the studies con-
ducted so far, many of the pre-hospital drugs do not af-
fect the prognosis of patients with ST-segment elevation 
myocardial infarction. Morphine has no effect on the an-
nual mortality rate in patients with STEMI [2], and a high 
concentration of oxygen in patients with uncomplicated 
myocardial infarction may be harmful [3]. Nitroglycerin 
is used to control the pain symptoms; however, it should 
not be routinely applied in patients with STEMI [4]. On 
the other hand, acetylsalicylic acid (ASA), the basic an-
tiplatelet drug, reduces mortality; therefore it should be 
administered as early as possible [4, 5]. ESC guidelines 
recommend the administration of an anticoagulant (un-
fractionated heparin, enoxaparin or bivalirudin) [4]. Un-
fractionated heparin (UFH) is easily available in Polish 
pre-hospital conditions; its additional advantage is the 
reversibility of the therapeutic effect after using prota-
mine sulphate [4]. In pre-hospital treatment, the second 
antiplatelet medication from the P2Y12 inhibitor group 
is a  standard. Until recently, clopidogrel has been rou-
tinely administered in a loading dose, but, as it has been 
proved, both prasugrel and ticagrelor allow clinical bene-
fits to be obtained as compared to clopidogrel in patients 
with acute coronary syndromes, and they are currently 
recommended as preferred drugs [6, 7]. The strategy of 
early pre-hospital administration of these medications 
compared to perioperative administration remains an 
open question, as the results of previous studies did not 
allow the strategy of pre-hospital administration of pras-
ugrel and ticagrelor to be included in the current recom-
mendations [8].
The administration of prasugrel before coronarogra-
phy is not recommended [5]. The improvement of care 
of patients with STEMI is possible due to minimization of 
the time from the onset of pain to the start of treatment. 
As studies indicate, early pharmacotherapy, especially 
including antiplatelet and anticoagulant medications, in 
a patient with infarction allows for their early efficacy [9]. 
At the time of the research, pre-hospital administration 
of clopidogrel was a model which was commonly used in 
Poland [10]. However, not all emergency medical teams 
(EMTs) could carry it out (depending on the type of EMT 
and its equipment), and the type of treatment applied 
could affect the treatment effect and survival of patients 
with STEMI [10]. 
Aim
The aim of the present study is to assess the influ-
ence of early administration of antiplatelet and anti-
coagulant medications by emergency medical teams 
in patients with STEMI on the frequency of in-hospital 
deaths as well as on the left ventricular ejection fraction 
assessed at discharge.
Material and methods
In the study, a  retrospective analysis of medical re-
cords (hospital records, medical card specifying rescue 
procedures performed by an emergency medical team) 
was used as a research method. The study included pa-
tients of the Krakow Centre of Invasive Cardiology, Elec-
trotherapy and Angiology brought by EMTs from the 
place where they fell ill from January 2011 to December 
2015 (excluding the whole of 2013, when organizational 
changes were introduced in the medical rescue teams, 
which had an influence on lower quality and the incom-
pleteness of data available in medical records). Ethical ap-
proval for this study was obtained (122/6120/185/2015)
Inclusion and exclusion criteria
All patients who were transported to hospital with 
a  diagnosis of myocardial infarction (534 patients) or 
other (62 patients), but in whom ST-segment elevation 
myocardial infarction was finally diagnosed, were select-
ed for further analysis. Of the 596 patients with STEMI 
brought by the emergency medical teams, 573 patients 
were included for further analysis, in the case of whom 
data on the ambulance travel time to the incident site 
were obtained. Patients sent from other hospitals, pa-
tients in the case of whom data on the ambulance travel 
time of a medical rescue team to the incident site were 
not available and patients treated in 2013 were exclud-
ed from further analysis. There were no other exclusion 
criteria. 
Statistical analysis
Statistical analyses were performed using Statistica 
10.0 (StatSoft, Inc. Statistica software, version 10.0) and 
IBM SPSS software version 23. For continuous variables, 
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the mean value and standard deviation (SD), minimum 
and maximum were determined. For qualitative vari-
ables, the absolute and percentage number of cases in 
relation to the whole analyzed group are presented. The 
nonparametric Mann-Whitney U test was used to com-
pare two samples. When comparing more samples, the 
nonparametric Kruskal-Wallis test was used. The Sha-
piro-Wilk test was used to assess the normality of the 
distribution. The chi-square test (χ2) was used to ana-
lyze the relationship of qualitative variables. The Pearson 
correlation coefficient or Spearman’s rank correlation 
coefficient was used to analyze the relationship between 
continuous variables. The value α = 0.05 was set as the 
level of statistical significance. In addition, univariate lo-
gistic regression as well as multivariate regression allow-
ing for the influence of more than one variable was used 
to investigate how the analyzed features were related to 
hospital death and reduced left ventricular contractility. 
A  series of independent logistic regression models (for 
each prehospital procedure separately) were performed 
to include variables which are significantly associated 
with the dependent variable, and to account for the rec-
ognized confounding factors. The results included four 
models: 1 – one-dimensional (raw), 2 – taking into ac-
count the influence of age and gender, 3 – model 2 and 
the analyzed time and distance, model 4 – model 3 and 
risk factors (hypercholesterolemia, hypertension, diabe-
tes, kidney function) and the occurrence of a shock. The 
results are presented as the odds ratio with a 95% con-
fidence interval.
Results
Characteristics of the studied population
Most of the patients were men (n = 375; 65.4%). The 
mean age was 64.4 ±11.8 years (minimum 35, maximum 
102). The mean age of women was 69.5 ±12.2 years, 
and of men 61.5 ±10.6 years (p < 0.01). Hypertension oc-
curred in 69.2% of patients (n = 395). 19.0% of patients 
(n = 109) had diabetes. During hospitalization, diabetes 
was diagnosed in 42 (7.3%) patients. In total, diabetes 
was present in 26.4% of patients (n = 151). The mean 
age was 64.4 ±11.8 years occurred in 60.6% of patients 
(n = 347). During hospitalization, hypercholesterolemia 
was additionally diagnosed in 120 (20.9%) patients. In 
total, hypercholesterolemia was present in 81.5% of pa-
tients (n = 467). Chronic renal failure occurred in 2 (3%) 
of patients. During hospitalization, based on the test re-
sults, chronic renal failure was diagnosed in a  total of 
10.1% of patients (n = 58). There is no known history of 
patients regarding previous myocardial infarction, per-
cutaneous coronary interventions or coronary bypass 
surgery.
The vast majority of patients received pre-hospital 
pharmacotherapy (n = 556; 97.0%). The MONA regimen 
was applied in full in 9.2% of patients (n = 53). In ad-
dition, 49.2% of patients received morphine (n = 282), 
61.0% oxygen (n = 350), 22.8% nitroglycerin (n = 131), 
and 84.6% acetylsalicylic acid (n = 485). Heparin was ad-
ministered to 46.0% of subjects (n = 264), and clopido-
grel to 19.2% (n = 110). These results can be explained by 
the fact that 45.2% of patients in this study were trans-
ported by basic medical emergency teams, which did not 
have heparin or clopidogrel available then and could not 
administer it in accordance with the law in force at that 
time. The use of two antiplatelet drugs is very rare in the 
material tested. If patients were not given pre-hospital 
antiplatelet or anticoagulant medication, they received 
these drugs upon admission to hospital. The exact timing 
of the administration of antiplatelet and anticoagulants 
prior to coronary angioplasty has not been recorded in 
the medical records and cannot be determined. It seems 
important to indicate the time from the first medical con-
tact (FMC), calculated from the arrival of the emergency 
medical team at the scene of the incident to the perfor-
mance of percutaneous coronary angioplasty, which was 
87 ±29 (74–103) min.
The influence of medication administration on 
left ventricular ejection fraction 
Echocardiographic assessment of left ventricular 
ejection fraction (LVEF) was performed in the hospital 
in 552 (96.3%) patients. It was evaluated at the day of 
discharge. A comparison of the distribution of the exam-
ined factors between subjects with normal left ventricu-
lar ejection fraction (LVEF ≥ 55%) and those whose LVEF 
was reduced (LVEF < 55%) is shown in Table I.
It was found that among pre-hospital procedures 
only the administration of a  second antiplatelet drug 
(clopidogrel) significantly affects left ventricular systol-
ic function. In the multidimensional model, the use of 
clopidogrel considerably decreased the risk of occurrence 
of reduced left ventricular ejection fraction (OR = 0.27; 
95% CI: 0.09–0.90), as shown in Table II.
The influence of medication administration on 
in-hospital death
In total, 38 people out of 573 subjects died in the hos-
pital (6.7%). In-hospital deaths occurred most frequently 
on day 1 of hospitalization (52.6%). Fifty-six patients did 
not receive any of the medications in the pre-hospital 
setting (aspirin, clopidogrel, heparin). Of this group, 9 pa-
tients died while in hospital.
The comparison of the distribution of examined fac-
tors between patients who died in hospital and those 
discharged from hospital is presented in Table III. 
Before hospitalization, hypercholesterolemia was di-
agnosed in 60.6% of patients (n = 347). During hospi-
talization, lipid metabolism disorders were additionally 
diagnosed in 120 (20.9%) patients. In total, hypercholes-
terolemia was present in 81.5% of patients (n = 467). 
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Based on the available data, it was not possible to es-
tablish why the mortality rate was higher in the group 
without diagnosed hypercholesterolemia, compared to 
the group with hypercholesterolemia (15.5% vs. 4.3%).
It was found that among procedures performed in 
a  pre-hospital setting only the administration of anti-
platelet and anticoagulant medications significantly af-
fects the frequency of in-hospital death. Administration 
of clopidogrel or heparin or a combination of both signifi-
cantly reduced the risk of in-hospital death in patients 
with STEMI (OR = 0.32; 95% CI: 0.13–0.78), as shown in 
Table IV. 
Table I. Comparison of dichotomous variables between individuals with normal (≥ 55%) and reduced (< 55%) 




≥ 55% < 55%
n % n %
Antiplatelet and/or  
anticoagulant medications
No medications 32 11.6 244 88.4 0.06
Heparin + clopidogrel 16 18.0 73 82.0
Heparin 20 12.0 147 88.0
Clopidogrel 6 30.0 14 70.0  
MONA regimen No 71 14.2 428 85.8 0.08
Yes 3 5.7 50 94.3
Sex Female 29 15.5 158 84.5 0.3
Male 45 12.3 320 87.7  
Shock No 67 14.0 413 86.0 0.3
Yes 7 9.7 65 90.3  
Diabetes No 61 15.0 347 85.0 0.07
Yes 13 9.0 131 91.0  
Hypercholesterolemia No 15 15.8 80 84.2 0.4
Yes 58 12.7 398 87.3  
Hypertension No 25 14.9 143 85.1 0.5
Yes 49 12.8 335 87.2  
Renal failure No 72 14.3 430 85.7 0.043 
Yes 2 4.0 48 96.0
p – p-value in χ2 test.
Table II. Relationship between occurrence of reduced maximal left ventricular ejection fraction and medication 
administration – one-dimensional and multidimensional models
Variable ORA 95% CI ORB 95% CI ORC 95% CI ORD 95% CI
Medications No 1 1 1 1
Heparin 0.96 0.53 1.75 0.97 0.54 1.76 0.89 0.47 1.67 0.89 0.48 1.64
Clopidogrel 0.31 0.11 0.85 0.33 0.12 0.93 0.28 0.095 0.83 0.27 0.09 0.80
Both 0.60 0.31 1.15 0.59 0.31 1.15 0.42 0.21 0.84 0.52 0.25 1.06
Distance 1.03 0.99 1.05 1.03 0.99 1.05
Time to PCI 1.001 0.999 1.003 1.01 0.995 1.02
MONA No 1 1 1 1
Yes 2.76 0.84 9.10 2.89 0.87 9.57 2.83 0.85 9.43 2.91 0.87 9.74
Distance 1.02 0.999 1.05 1.02 0.998 1.05
Time to PCI 1.01 0.996 1.02 1.01 0.996 1.02
OR – odds ratio, Amodel 1 = raw data, Bmodel 2 = model 1 + age + sex, Cmodel 3 = model 1 = 2 + age + sex + distance + time to PCI, Dmodel 4 = model 2 + diabetes + 
hypertension + hypercholesterolemia +  renal failure + shock.
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Table III. Comparison of dichotomous variables between patients who died in hospital and those who were 
discharged from hospital
Variable Death P-value 
No Yes
n % n % 
Antiplatelet and/or  
anticoagulant drugs
No medications 264 91.7 24 8.3 0.08
Heparin + clopidogrel 88 98.9 1 1.1
Heparin 163 93.1 12 6.9
Clopidogrel 20 95.2 1 4.8  
MONA regimen No 484 93.1 36 6.9 0.4
Yes 51 96.2 2 3.8
Sex Female 176 88.9 22 11.1 0.002
Male 359 95.7 16 4.3
Shock No 471 96.1 19 3.9 0.001
Yes 64 77.1 19 22.9
Diabetes No 399 95.0 21 5.0 0.03
Yes 136 90.1 15 9.9
Hypertension No 162 92.0 14 8.0 0.3
Yes 373 94.4 22 5.6
Hypercholesterolemia No 87 84.5 16 15.5 < 0.001
Yes 447 95.7 20 4.3
Kidney disfunction No 494 95.9 21 4.1 < 0.001
Yes 41 70.7 17 29.3
p – p-value in χ2 test.
Table IV. Relationship between occurrence of in-hospital death and performance of pre-hospital procedures – 
one- and multidimensional models
Variable ORA 95% CI ORB 95% CI ORC 95% CI ORD 95% CI
Medications No 1 1 1,00 1,00
Yes 0.66 0.35 1.26 0.55 0.28 1.10 0.47 0.22 1.00 0.32 0.13 0.78
Distance 0.98 0.95 1.01 0.97 0.94 1.01
Time to PCI 1.01 1.001 1.02 1.01 0.997 1.02
MONA regimen No 1 1 1 1
Yes 0.55 0.13 2.35 0.72 0.16 3.13 0.81 0.18 3.56 1.26 0.26 6.03
Distance 0.98 0.95 1.005 0.97 0.94 1.01
Time to PCI 1.01 1.001 1.02 1.01 0.997 1.02
OR – odds ratio, Amodel 1 = one-dimensional model, Bmodel 2 = model 1 + age + sex, Cmodel 3 = model 2 + distance + time to PCI, Dmodel 4 = model 2 + diabetes + 
hypertension + hypercholesterolemia + renal failure + shock.
Limitations of the study
A  limitation of this study is the fact that it is of an 
observational nature and is a  registry study with retro-
spective data obtained from information contained in 
medical records. Therefore, it was not possible to verify 
the data contained therein, such as the observed differ-
ences in reporting the same time by emergency medical 
teams and the hemodynamics laboratory. Additionally, in 
the long follow-up period (from 2010 to 2015), patients’ 
treatment in terms of hospital procedures may have 
changed, which has not been included in this analysis.
Discussion
Early pharmacotherapy in myocardial infarction, es-
pecially involving antiplatelet and anticoagulant med-
ications in a  patient with myocardial infarction, allows 
Magdalena Żurowska-Wolak et al. Pre-hospital treatment of STEMI
44 Advances in Interventional Cardiology 2021; 17, 1 (63)
for their early efficacy. Most studies argue for pre-hos-
pital administration of clopidogrel in the case of STEMI, 
which has a positive effect on in-hospital mortality, but 
the value of early administration of this medication is 
not clearly confirmed due to limited data from clinical re-
search on this strategy. In our study we observed a lower 
percentage of in-hospital deaths (1.1%) among patients 
to whom clopidogrel and heparin were administered 
prehospitally, as compared to those who did not receive 
these medications (8.3%) or who received heparin alone 
(6.9%) or clopidogrel alone (4.8%) (p = 0.08).
In the multidimensional model, administration of 
heparin and/or clopidogrel significantly decreased the 
risk of in-hospital death (OR = 0.32; 95% CI: 0.13–0.78). 
However, no significant difference was observed after 
discharge. A reduction in in-hospital mortality in patients 
who received clopidogrel before arrival at the hemody-
namics laboratory was also observed in the analysis of 
5,955 patients from the Austrian register of acute cor-
onary syndromes (3.4% vs. 6.1%, p < 0.01) [11]. In con-
trast, in Minneapolis (the U.S.), in a group of 2,014 pa-
tients with STEMI, no significant decline in in-hospital 
mortality (2.8% vs. 3.2%, p = 0.66) or 1-year mortality 
(5.4% vs. 6.1%, p = 0.59) was found in the group of pa-
tients to whom clopidogrel had been previously admin-
istered [12].
Similarly, in the Netherlands, in a  group of 1,365 
patients who were given clopidogrel in an ambulance 
compared to 1,110 patients who were given clopidogrel 
in hospital there was no difference in the percentage 
of deaths, this time in a 30-day and a 1-year follow-up 
(3.4% vs. 3.2%, p = 0.76 and 6.1% vs. 5.9%, p = 0.80) 
[13]. Meanwhile, in a  study by Polish authors, among 
1,667 patients with STEMI who were given clopidogrel in 
the pre-hospital phase or during coronary angiography, 
non-significantly lower 1-year mortality was observed 
in the group of early administration of the medication 
(8.8% vs. 12.2%, p = 0.07), which could not be confirmed 
after taking into account confounding factors [14].
Nevertheless, a Swedish registry study, which includ-
ed 13,847 patients, showed a significant reduction in the 
risk of death in a 30-day follow-up (HR = 0.70; 95% CI: 
0.57–0.85) and a 1-year follow-up (HR = 0.76; 95% CI: 
0.64–0.90) after pre-hospital administration of clopido-
grel in patients with STEMI treated with PCI, compared to 
patients who did not receive this medication [15].
Similarly, in the randomized CIPAMI trial assessing 
the difference between early (pre-hospital) clopidogrel 
administration and its administration in hospital (after 
coronarography and before angioplasty), a lower number 
of deaths, fewer recurrences of myocardial infarction and 
fewer revascularization procedures during hospitaliza-
tion were observed in the group of patients who received 
clopidogrel in an ambulance, but this result did not reach 
statistical significance (7.5% vs. 2.5%, p = 0.06) [16].
The meta-analysis conducted by Nairooz et al., which 
comprised 16 studies involving 61,517 patients with in-
farction who received invasive treatment, also showed 
a  reduction in 30-day follow-up mortality in the group 
of early clopidogrel administration (2.8% vs. 4.1%, OR = 
0.70; 95% CI: 0.58–0.85, p = 0.0003) compared to periop-
erative administration [17].
It should be emphasized that in most of the cited 
studies [11–13, 15], all patients received heparin in addi-
tion to clopidogrel. Also in our study, the lowest number 
of in-hospital deaths was observed when these medica-
tions were administered together. 
The analysis of patients in the APPOSITION III study 
(evaluating the usefulness of the implantation of self-ex-
pandable stents during primary PCI) shows that in the 
Netherlands, in a  group of 407 patients, 92% of them 
received ASA in the pre-hospital phase, 81% received 
clopidogrel, and 74% received heparin. In France, among 
131 patients this percentage was as follows, respectively: 
90%, 82%, 50% [18]. In Germany, in the group of 2,266 
patients of emergency teams, as many as 96.2% received 
ASA, clopidogrel and heparin [19].
The use of heparin in the analyzed material is com-
parable to French data, but much lower than in the Neth-
erlands and Germany. In the material studied, the use 
of the second antiplatelet drug, i.e. clopidogrel, is rare, 
especially against the background of the quoted studies. 
This result can be explained by the fact that 45.2% of 
patients in this study were transported by basic emer-
gency teams, which were not equipped with heparin or 
clopidogrel at that time. 
The study showed that among pre-hospital proce-
dures only the administration of a  second antiplatelet 
drug (clopidogrel) significantly affects left ventricular 
systolic function. In the multidimensional model, the use 
of clopidogrel considerably lowered the risk of develop-
ing a  reduced left ventricular ejection fraction; among 
the procedures performed in the pre-hospital setting, 
only the administration of antiplatelet and anticoagulant 
medications significantly affects the frequency of death 
in hospital. Administration of clopidogrel or heparin, or 
a combination of both of these medications, significantly 
reduced the risk of in-hospital death in STEMI patients.
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